Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Print publication year: 2004
  • Online publication date: December 2009

19 - The clinical value and meaning of health-related quality-of-life outcomes in oncology

Summary

The clinical value of measuring health-related quality of life

Common clinical outcomes

Before the modern era of objectivity in clinical oncology research, reports of the effects of therapy were often based on an individual clinician's experience (case reports and series). As awareness of the advantages of research objectivity increased, several clinical outcomes, including overall survival, median survival time, tumor-free survival, progression-free survival, time to progression, and frequency and duration of tumor response, were accepted and widely used. Of these, overall survival is considered as being the “hardest” endpoint, i.e., least likely to be subject to misinterpretation, and tumor response the “softest” endpoint.,

In addition, the concept of levels of evidence was introduced.– The highest level of evidence, Level I, consists of data from meta-analysis of several phase III randomized controlled clinical trials (RCTs) or a very large, phase III trial containing several hundred patients. The lowest level of evidence, Level IV, is data derived from small, uncontrolled case series or reports. Currently, institutions collaborate with each other to enroll the large number of patients needed to produce Level I evidence, and eligibility criteria for patient enrollment are increasingly stringent in order to control as many clinical variables as possible.

The interpretation of clinical trials has been aided by the collection of toxicity data. As with response and survival data, there has been an attempt to become more comprehensive by collecting very detailed information with uniform grading systems.

REFERENCES
Simon, R. (1993). Design and conduct of clinical trials. In Cancer. Principles and Practice of Oncology, (Fourth Edition), ed. V. T. DeVita Jr., S. Hellman, S. Rosenberg, pp. 416–40. Philadelphia, PA: JB Lippincott Co
Warr, D., McKinney, S., Tannock, I. (1984). Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor responseJournal of Clinical Oncology 2:1041–6
Cook, D. J., Guyatt, G. H., Laupacis, A., Sackett, D. L. (1992). Rules of evidence and clinical recommendation on the use of antithrombotic agentsChest 102 (Suppl. 4):305S–11S
Sackett, D. L. (1993). Rules of evidence and clinical recommendations for the management of patientsCanadian Journal of Cardiology 9:487–9
Sackett, D. L., Cook, D. J. (1993). Can we learn anything from small trials?Annals of the New York Academy of Sciences 703:25–31
Franklin, H. R., Simonetti, G. P., Dubbelman, A. C.et al. (1994). Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomitingAnnals of Oncology 5:113–17
Karnofsky, D. A., Abelman, W. H., Craver, L. F., Burchenal, J. H. (1948). The use of nitrogen mustards in the palliative treatment of carcinomaCancer 1:634–56
Zubrod, C. G., Schneiderman, M., Frei, E. III. et al. (1960). Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases 11:7–33
Ware, J. E. Jr., (1991). Measuring functioning, well-being, and other generic health concepts. In Effect of Cancer on Quality of Life, ed. D. Osoba, pp. 7–23. Boca Raton, FL: CRC Press
Slevin, M. L., Plant, H., Lynch, D., Drinkwater, J., Gregory, W. M. (1988). Who should measure quality of life, the doctor or the patient?British Journal of Cancer 57:109–12
Sneeuw, K. C. A., Aaronson, N. K., Sprangers, M. A. G., Detmar, S. B., Wever, L. D. V., Schornagel, J. H. (1998). Comparison of patient and proxy EORTC QLQ-C30 ratings in assessing the quality of life of cancer patients.Journal of Clinical Epidemiology 51:617–31
Osoba, D., Rusthoven, J. J., Turnbull, K. A., Evans, W. K., Shepherd, F. A. (1998). Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.Journal of Clinical Oncology 3:1478–85
Stephens, R. J., Hopwood, P., Girling, D. J. (1999). Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise.British Journal of Cancer 79:533–44
Savage, C., Pater, J. L., Tu, D., Norris, B. (2002). He said/she said: how well do common toxicity criteria and quality of life agree on patient symptoms?Proceedings of the American Society of Clinical Oncology 21:382a (abstract 1540)
Osoba, D. (1991). Measuring the effect of cancer on quality of life. In Effect of Cancer on Quality of Life, ed. D. Osoba, pp. 25–40. Boca Raton, FL: CRC Press
Osoba, D., Aaronson, N. K., Till, J. E. (1999) A practical guide for selecting quality-of-life measures in clinical trials and practice. In Effect of Cancer on Quality of Life, ed. D. Osoba, pp. 89–104. Boca Raton, FL: CRC Press
Guyatt, G. H., Veldhuzen Van Zanten, S. J. O., Feeny, D. H., Patrick, D. L.. (1989). Measuring quality of life in clinical trials: a taxonomy and review.Canadian Medical Association Journal 140:1441–8
Jaeschke, R., Guyatt, G. D., Cook, D. (1992). Quality of life instruments in the evaluation of new drugs.Pharmacoeconomics 1:84–94
Osoba, D. (1995). Measuring the effect of cancer on health-related quality of lifePharmacoeconomics 7:308–19
Mackworth, N., Fobair, P., Prados, M. D. (1992). Quality of life self-reports from 100 brain tumor patients: comparisons with Karnofsky Performance ScoresJournal of Neuro-Oncology 14:243–53
Schaafsma, J., Osoba, D. (1994). The Karnofsky performance status scale re-examined: a cross-validation with the EORTC-C30Quality of Life Research 3:413–24
Hjermstad, M. J., Fayers, P. M., Bjordal, K., Kaasa, S. (1998). Health related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire: the QLQ-C30(+3).Journal of Clinical Oncology 16:1188–96
Klee, M., Roenvald, M., Machin, D. (1997). Quality of Life of Danish women: population-based norms for the EORTC QLQ-C30.Quality of Life Research 6:27–34
Michelson, H., Bolund, C., Nilsson, B., Brandberg, Y. (2000). Health-related quality of life measured by the EORTC QLQ-C30 — reference values from a large sample of the Swedish population.Acta Oncologica 39:477–84
Gandek, B., Ware, J. E., Aaronson, N. K.et al. (1998). Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA project.Journal of Clinical Epidemiology 51:1149–58
Fayers, P., Weeden, S., Curran, D. (1998). EORTC QLQ-C30 Reference Values. Brussels: EORTC Quality of Life Study Group, EORTC Data Centre
Allen-Mersch, T. G., Earlam, S., Fordy, C., Abrams, K., Houghton, J. (1994). Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastasesLancet 344:1255–60
Clavel, M., Soukop, M., Greenstreet, Y. C. A., (1993). Improved control of emesis and quality of life with ondansetron in breast cancerOncology 50:180–5
Coates, A., Gebski, V., Bishop, J. F.et al. (1987). Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.New England Journal of Medicine 317:1490–5
Osoba, D., Brada, M., Yung, W. K. A., Prados, M. (2000). Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.Journal of Clinical Oncology 18:1481–91
Osoba, D., Brada, M., Yung, W. K. A., Prados, M. (2000). Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.European Journal of Cancer 36:1788–95
Osoba, D., Northfelt, D. W., Budd, D. W., Himmelberger, D. (2001). Effect of treatment on health-related quality of life in AIDS-related Kaposi's sarcoma; a randomized trial of pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine.Cancer Investigation 19:573–80
Murray, N., Livingston, R. B., Shepherd, F. A.et al. (1999). Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.Journal of Clinical Oncology 17:2300–8
Hürny, C., Bernhard, J., Coates, A. S.et al. (1996). Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group.Lancet 347:1279–84
Fairclough, D. L., Fetting, J. H., Cella, D., Wonson, W., Moinpour, C. M. (1999). Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant chemotherapy. Eastern Cooperative Oncology Group (ECOG).Quality of Life Research 8:723–31
Osoba, D. (1999). What has been learned from measuring health-related quality of life in clinical oncology.European Journal of Cancer 35:1565–70
Cutler, D. M., Richardson, E. (1997). Measuring the health of the U.S. population. In Brookings Papers on Economic Activity: Microeconomics, ed. M. C. Bailey, P. C. Reiss, C. Winston, pp. 217–71. Washington, DC: Brookings Institute
Osoba, D., Zee, B., Sadura, A., Pater, J., Quirt, I. (1993). Measurement of quality of life in an adjuvant trial of gamma interferon versus levamisole in malignant melanoma. In Adjuvant Therapy of Cancer VII, ed. S. E. Salmon, pp. 412–16. Philadelphia, PA: JB Lippincott Co
Coates, A., Gebski, V., Signorini, D.et al. (1992). Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group.Journal of Clinical Oncology 10:1833–8
Coates, A., Porzsolt, F., Osoba, D. (1997). Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.European Journal of Cancer 33:1025–30
Coates, A. S., Hürny, C., Peterson, H. F.et al. (2000). Quality-of-life scores predict outcome in metastatic but not early breast cancer.Journal of Clinical Oncology 18:3768–74
Coates, A. S., Thomson, D., McLeod, G. R. M.et al. (1993). Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma.European Journal of Cancer 29A:1731–4
Earlam, S., Glover, C., Fordy, C., Burke, D., Allen-Mersh, T. G. (1996). Relation between tumour size, quality of life, and survival in patients with colorectal liver metastases.Journal of Clinical Oncology 14:171–5
Kaasa, S., Mastekaasa, A., Lund, E. (1989). Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease.Radiotherapy Oncology 15:235–42
Ganz, P. A., Lee, J. J., Siau, J. (1991). Quality of life assessment. An independent prognostic variable for survival in lung cancer.Cancer 67:3131–5
Blazeby, J. M., Brookes, S. T., Alderson, D. (2001). The prognostic value of quality of life scores during treatment for oesophageal cancer.Gut 49:227–30
Dancey, J., Zee, B., Osoba, D.et al. (1997). Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy.Quality of Life Research 6:151–8
Herndon, J. E. Jr., Fleishman, S., Kornblith, A. B., Kosty, M., Green, M. R., Holland, J. (1999). Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?Cancer 85:333–40
Medical Research Council Working Party (1993). A randomized trial of three or six courses of etoposide, cyclophosphamide, methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer. (SCLC) II: quality of life.British Journal of Cancer 68:1157–66
Tannock, I. F., Osoba, D., Stockler, M. R.et al. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer; a Canadian randomized trial with palliative end points.Journal of Clinical Oncology 14:1756–64
Osoba, D., Tannock, I. F., Ernst, S., Neville, J. (1999). Health-related quality of life in men with metastatic prostate cancer treated by prednisone alone or mitoxantrone and prednisone.Journal of Clinical Oncology 17:1654–63
Demetri, G. D., Kris, M., Wade, J., Degos, L., Cella, D. (1998). Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study.Journal of Clinical Oncology 16:3412–25
Rowland, K. M. Jr., Loprinzi, C. L., Shaw, E. G.et al. (1996). Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group Study.Journal of Clinical Oncology 14:135–41
Simons, J. P., Aaronson, N. K., Vansteenkiste, J. F.et al. (1996). Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicentre study.Journal of Clinical Oncology 14:1077–84
Bruera, E., Ernst, S., Hagen, N.et al. (1998). Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.Cancer Prevention and Control 2:74–8
Porter, A. T., McEwan, A. J. B., Powe, J. E.et al. (1993). Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.International Journal of Radiation Oncology, Biology, and Physics 25:805–13
Seymour, M. T., Slevin, M. L., Kerr, D. J.et al. (1996). Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer.Journal of Clinical Oncology 14:2282–8
Ganz, P. A. (2001). Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life.Journal of the National Cancer Institute Monograph 30:130–4
Moinpour, C. M., Lovato, L. C., Thompson, I. M.et al. (2000). Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors.Journal of Clinical Oncology 18:1942–53
Hays, R. D., Anderson, R., Revicki, D. (1993). Psychometric considerations in evaluating health-related quality of life measures.Quality of Life Research 2:441–9
Hays, R. D., Anderson, R. T., Revicki, D. (1998). Assessing reliability and validity of measurement in clinical trials. In Quality of Life Assessment in Clinical Trials, ed. M. J. Staquet, R. D. Hays, P. M. Fayers, pp. 169–23. Oxford: Oxford University Press
Revicki, D. A., Kaplan, R. M. (1993). Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.Quality of Life Research 2:477–87
Torrance, G. W. (1986). Measurement of health state utilities for economic appraisal.Journal of Health Economics 5:1–30
Torrance, G. W., Feeny, D. (1989). Utilities in quality-adjusted life years.International Journal of Technology Assessment in Health Care 5:559–75
Kaplan, R. M., Feeny, D., Revicki, D. A. (1993). Methods for assessing relative importance in preference based outcome measures.Quality of Life Research 2:467–75
Feeny, this volume, Chapter 4
O'Brien, this volume, Chapter 25
Detmar, S., Muller, M. J., Schornagel, J. H., Wever, L. D., Aaronson, N. K. (2002). The role of health-related quality of life considerations in palliative chemotherapy treatment decisionsJournal of Clinical Oncology 20:1056–62
Levine, M. N., Gafni, A., Markham, B., MacFarlane, D. (1992). A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer.Annals of Internal Medicine 117:53–8
Whelan, T. J., Levine, M. N., Gafni, A.et al. (1995). Breast irradiation postlumpectomy: development and evaluation of a decision instrument.Journal of Clinical Oncology 13:847–53
Osoba, D. (2002). A taxonomy of the uses of health-related quality of life (HRQOL) instruments in cancer care and the clinical meaningfulness of the results.Medical Care 40 (Suppl. 3):S31–8
Detmar, S. B., Aaronson, N. K. (1998). Quality of life assessment in daily clinical oncology practice: a feasibility study.European Journal of Cancer 34:1181–6
Velikova, G., Brown, J. M., Smith, A. B., Selby, P. J. (2002). Computer-based quality of life questionnaires may contribute to doctor—patient interactions in oncology.British Journal of Cancer 86:51–9
Murray, C. J. L., Lopez, A. D. (1997). Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.Lancet 349:1436–42
World Health Organization (2000). The World Health Report 2000: Health Systems: Improving Performance. Geneva: World Health Organization
Goldie, A. J., Kuntz, K. M., Weinstein, M. C., Freedberg, K. A., Palefsky, J. M. (2000). Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.American Journal of Medicine 108:634–41
Neilson, A. R., Whynes, D. K. (1995). Cost-effectiveness of screening for colorectal cancer: a simulation model.IMA Journal of Mathematically Applied Medical Biology 12:355–67
Norum, J. (2000). Adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF) in breast cancer — is it cost-effective?Acta Oncologica 39:33–9
Brown, M. L, Lipscomb, J., Snyder, C. (2001). The burden of illness in cancer: economic cost and quality of life.Annual Review of Public Health 22:91–113
Lydick, E., Epstein, R. S. (1993). Interpretation of quality of life changes.Quality of Life Research 2:221–6
Osoba, D., Rodrigues, G., Myles, J., Zee, B., Pater, J. (1998). Interpreting the significance of changes in health-related quality-of-life scores.Journal of Clinical Oncology 16:139–44
Bernhard, J., Gelber, R. D., ed. (1998). Workshop on Missing Data in Quality of Life Research in Cancer Clinical Trials: Practical and Methodological Issues. Statistics of Medicine 17:511–796
Fairclough, D. L. (2002). Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC
Sloan, this volume, Chapter 18, pp. 362–85
Cohen, J. (1977). Statistical Power Analysis for the Behavioural Sciences. New York: Academic Press
Kazis, L. E., Anderson, J. J., Meenan, R. F. (1989). Effect sizes for interpreting changes in health status.Medical Care 27 (Suppl. 3):S178–89
King, M. T. (1996). The interpretation of scores from the EORTC Quality of Life Questionnaire QLQ-C30.Quality of Life Research 5:555–67
Jacobson, N. S., Roberts, L. J., Berns, S. B., McGlinchey, J. B. (1999). Methods for defining and determining the clinical significance of treatment effects: description, application and alternatives.Journal of Consulting Clinical Psychology 67:300–7
Salsburg, D. S., Turner, R. S. (1992). Defining clinically meaningful units of change for health outcome research.Quality of Life Newsletter 3:1
Wyrwich, K., Nienaber, N. A., Tierney, W., Wolinsky, F. (1999). Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life.Medical Care 37:469–78
Wyrwich, K., Tierney, W., Wolinsky, F. (1999). Further evidence supporting a SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life.Journal of Clinical Epidemiology 52:861–73
Wyrwich, K. W., Wolinsky, F. G. (2000). Identifying meaningful intra-individual change standards for health-related quality of life measures.Journal of Evaluating Clinical Practice 6:39–45
Jaeschke, R., Singer, J., Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference.Controlled Clinical Trials 10:407–15
Juniper, E. D., Guyatt, G. H., Willan, A., Griffith, L. E. (1994). Determining a minimal important change in a disease-specific quality of life questionnaire.Journal of Clinical Epidemiology 47:81–7
Ware, J. E., Keller, S. D. (1996). Interpreting general health measures. In Quality of Life and Pharmacoeconomics in Clinical Trials, ed. B. Spilker, pp. 445–60. Philadelphia, PA: Lippincott-Raven
Guyatt, G., Osoba, D., Wu, A., Wyrwich, K., Norman, G. and the Clinical Significance Consensus Meeting Group (2002). Methods to explain the clinical significance of health status measures.Mayo Clinic Proceedings 77:371–83
Cella, D., Hahn, E., Dineen, K. (2002). Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening.Quality of Life Research 11:207–21
Cohen, R. S., Mount, B. M. (2000). Living with cancer: “Good” days and “bad” days — what produces them?Cancer 89:1854–65
Ringash, G. J., Redelmeier, D. A., O'Sullivan, B., Bezjak, A. A. (1999). Asymmetry of good and bad minimal important differences in quality of life for laryngeal cancer patients.Quality of Life Research 8:604 (abstract 214)
Rodrigues, G., Bezjak, A., Osoba, D.et al. (2000). Measuring patient perception of health-related quality-of-life changes using the Subjective Significance Questionnaire.Quality of Life Research 9:256 (abstract 1404)
Ross, M. (1989). Relation of implicit theories to the construction of personal histories.Psychological Reviews 96:341–7
Norman, G. R., Stratford, P., Regehr, G. (1997). Methodological problems in the retrospective computation of responsiveness to change: the lesson of Cronbach.Journal of Clinical Epidemiology 50:869–79
Sneeuw, K., Muller, M., Aaronson, N. (2000). Interpreting the significance of changes in EORTC QLQ-C30 and COOP/WONCA scores.Quality of Life Research 9:256 (abstract 1416)
Sprangers, M. A. G., Schwartz, C. E. (1999). Integrating response shift into health-related quality of life research: a theoretical model.Social Science and Medicine 48:1507–15
Sprangers, M. A. G., Schwartz, C. E. (1999). The challenge of the response shift for quality-of-life based clinical oncology research (Editorial).Annals of Oncology 10:747–9
Jansen, S. J. T., Stiggelbout, A. M., Nooij, E. M., Noordijk, E. M., Kievit, J. (2000). Response shift in quality of life measurement in early-stage breast cancer patients undergoing radiotherapy.Quality of Life Research 9:603–15
Osoba, D., Brada, M., Prados, M. D., Yung, W. K. A., (2000). Effect of disease burden on health-related quality of life in patients with malignant gliomas.Neuro-Oncology 2: 221–8
Hornbrook, this volume, Chapter 24
Cella, D., Bullinger, M., Scott, C., Gorkin, L., Barofsky, I., and the Clinical Significance Consensus Meeting Group. (2002). Group versus individual approaches to understanding the clinical significance of differences or changes in quality of life.Mayo Clinic Proceedings 77:384–92
Sloan, J. A., Aaronson, N., Cappelleri, J. C., Fairclough, D. L., Varricchio, C., and the Clinical Significance Consensus Meeting Group. (2002). Assessing the clinical significance of single items relative to summated scores.Mayo Clinic Proceedings 77:479–87
Frost, M. H., Bonomi, A. E., Ferrans, C. E., Wong, G. Y., Hays, R. D., and the Clinical Significance Consensus Meeting Group. (2002). Patient, clinician and population perspectives on determining the clinical significance of quality-of-life scores.Mayo Clinic Proceedings 77:488–94
Symonds, T., Berzon, R., Marquis, P., Rummans, T., and the Clinical Significance Consensus Meeting Group (2002). The clinical significance of quality-of-life results: practical considerations for specific audiences.Mayo Clinic Proceedings 77:572–83
Fayers, P., Machin, D. (2000). Quality of Life: Assessment, Analysis and Interpretation. Chichester: John Wiley & Sons
Sprangers, M. A. G., Moinpour, C., Moynihan, T. J., Patrick, D. L., Revicki, D. A., and the Clinical Significance Consensus Meeting Group. (2002). Assessing meaningful change over time in quality of life: a users' guide for clinicians.Mayo Clinic Proceedings 77:561–71
Osoba, D. (1998). Guidelines for measuring health-related quality of life in clinical trials. In Quality of Life Assessment in Clinical Trials, ed. M. J. Staquet, R. D. Hays, P. M. Fayers, pp. 19–35. Oxford: Oxford University Press
Staquet, M., Berzon, R., Osoba, D., Machin, D. (1996). Guidelines for reporting results of quality of life assessments in clinical trials.Quality of Life Research 5:496–502
Guyatt, G. H., Juniper, E. F., Walter, S. D., Griffith, L. E., Goldstein, R. S. (1998). Interpreting treatment effects in randomised trials.British Medical Journal 316:690–3
Nunnally, J. C., Bernstein, I. H. (1994). Psychometric Theory (3rd Edition), pp. 264–5. New York, NY: McGraw-Hill, Inc
Revicki, D. A., Cella, D. F. (1997). Health status assessment for the twenty-first century: item response theory, item banking and computer adaptive testing.Quality of Life Research 6:595–600
Revicki, D. A., Osoba, D., Fairclough, D.et al. (2000). Recommendation on health-related quality of life research to support labeling and promotional claims in the United States.Quality of Life Research 9:887–900
Leidy, N. K., Revicki, D. A., Geneste, B. (1999). Recommendations for evaluating the validity of quality of life claims for labeling and promotion.Value in Health 2:113–27
Ganz, P. A. (1995). Impact of quality of life outcomes on clinical practice.Oncology 9 (Suppl. 11):61–5
Osoba, D., Till, J. E., Pater, J. L., Young, J. R. (1995). Health-related quality of life: measurement and clinical application. A workshop report.Canadian Journal of Oncology 5:338–431